A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma in Israel.
Irreversible proteasome inhibitor carfilzomib appears to cause reticulocytosis in multiple myeloma by inhibiting terminal erythroid maturation.
Patients who received autologous transplant followed by allogeneic transplant experienced improved progression-free survival.
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
Plitidepsin plus dexamethasone yielded improved progression-free and overall survival compared with dexamethasone alone.
Factors associated with poor adherence to specific guideline-recommended supportive care measures involved patient race and site of care.
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
All-oral regimen linked to higher satisfaction with treatment convenience in relapsed, refractory MM
Cardiovascular adverse events were more common with carfilzomib therapy and within the first 3 months of treatment.
For patients receiving drug therapy, economic burden substantial across lines of therapy
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Progressive MGUS and light-chain MGUS were both associated with skewed serum free light chain ratios.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Very good partial response or better was seen in nearly two-thirds of patients receiving the triplet treatment.
Patients who were naive to daratumumab experienced an overall response rate of 91.7%; median progression-free survival in this cohort was not reached.
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Median overall survival was 3.6 years for patients who received upfront therapy and 4.2 years for patients who did not.
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Lenalidomide reduced the risk of disease progression in patients with intermediate- or high-risk smoldering multiple myeloma, but discontinuation rates were high.
Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.
When added to bortezomib, thalidomide, and dexamethasone, daratumumab was associated with higher rates of measurable disease negativity.
Patients with both high and standard cytogenetic risk who received daratumumab experienced increased PFS.
Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.
Researchers developed a new model for risk stratification in patients with SMM based on updated criteria.
Median progression-free survival was 22.3 months in patients receiving carfilzomib and 22.1 months in patients receiving bortezomib.
Identifying patients with smoldering myeloma at high risk for disease progression may allow for implementation of better treatment strategies.
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Translocations of IgL occurred in approximately 10% of patients with newly diagnosed multiple myeloma.
Pomalidomide, cyclophosphamide, and dexamethasone triplet therapy for relapsed/refractory multiple myeloma had an overall response rate of 76%.
This action does not impact currently approved indications for venetoclax.
Researchers were able to gain a better understanding of the clonal genetic landscape of relapsed multiple myeloma following autologous stem cell transplantation.
The Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex (daratumumab; Janssen), which provides clinicians the option of splitting the first infusion of daratumumab over 2 consecutive days.
Advances in genetic and molecular assessment strategies have led to improved outcomes for patients with multiple myeloma.
Each of 3 reduced intensity conditioning regimens yielded similar clinical outcomes in patients with multiple myeloma undergoing allogeneic stem cell transplant.
Though imaging provides a powerful tool for diagnosis and treatment of multiple myeloma, choosing the appropriate technique depends on many factors.
Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.
Researchers emphasized the need for novel condition regimens and a standardized post-transplantation maintenance approach.
Patients who did not have immune dysregulation had higher overall survival compared with patients who had immune dysregulation.
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
Stringent CR criteria may not predict clinical outcomes for patients with MM.
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
Patients who received elotuzumab plus pomalidomide and dexamethasone demonstrated longer progression-free survival.
Therapeutic options for myeloma bone disease include bisphosphonates, immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies.
Bortezomib-based induction therapy is the current standard of care for patients with multiple myeloma, but thalidomide is a promising contender.
Intermediate-dose cytarabine has been demonstrated to have high efficacy as a chemomobilization agent.